Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision history on the page was updated with new August 2026 entries. A new Revision: v3.6.6 supersedes the previous Revision: v3.6.5.SummaryDifference0.1%

- Check20 days agoChange DetectedA new publication citation by Leighl NB et al. was added to the Publications section. The citation describes a plain-language summary of subcutaneous versus intravenous amivantamab plus lazertinib in EGFR-mutated NSCLC and notes that it is online ahead of print.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4. This indicates a minor update to the page's version metadata rather than any changes to study content.SummaryDifference0.0%

- Check41 days agoChange DetectedTwo new update dates (2026-07-31 and 2026-07-30) were added and two earlier dates (2026-07-06 and 2026-07-02) were removed from the study's record history, reflecting maintenance of the listing's update chronology.SummaryDifference0.1%

- Check56 days agoChange DetectedThe page's revision number was updated from v3.6.3 to v3.6.4, signaling a small platform or content update rather than a change to study data.SummaryDifference0.0%

- Check70 days agoChange DetectedNew update timestamps (2026-07-06, 2026-07-02, 2026-07) were added and older ones (2026-06-08, 2026-06-04, 2026-06) removed in the study's record dates, reflecting the current update chronology.SummaryDifference0.1%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.